Erythropoietin and cancer, a double-edged sword

Leukemia Research

Volumn 33, Issue 1, 2009, Pages 1-4

  Ribatti, Domenico ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Erythropoietin; Erythropoietin receptor; Erythropoietin stimulating agents; Tumor progression

Indexed keywords

CISPLATIN; DACARBAZINE; ERYTHROPOIETIN; ERYTHROPOIETIN ANTIBODY; ERYTHROPOIETIN RECEPTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; EXERCISE TOLERANCE; FATIGUE; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN BLOOD LEVEL; HUMAN; LYMPHOMA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOEMBOLISM;

ANEMIA; DISEASE PROGRESSION; ERYTHROPOIETIN; HUMANS; NEOPLASMS; RECEPTORS, ERYTHROPOIETIN; RNA, MESSENGER; SURVIVAL RATE;

EID: 55049111452     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.06.004     Document Type: Editorial

References (65)

1. Knight K., Wade S., and Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 116 (2004) 11S-26S
2. Groopman J.E., and Itri L.M. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91 (1999) 1616-1634
3. Miller C.B., Jones R.J., Piantadosi S., Abeloff M.D., and Spivak J.L. Decreased erythropietin response in patients with the anemia of cancer. N Engl J Med 322 (1990) 1689-1692
4. Barosi G., Marchetti M., and Liberato N.L. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anemia. Br J Cancer 78 (1998) 781-787
5. Dunst J. Hemoglobin level and anemia in radiation oncology: prognostic impact and therapeutic implications. Semin Oncol 27 (2000) 4-8
6. Seidenfeld J., Piper M., Flamm C., Hasselblad V., Armitage J.O., Bennett C.L., et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 93 (2001) 1204-1214
7. Bottomley A., Thomas R., Van S.K., Flechtner H., and Djulbegovic B. Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?. Lancet Oncol 3 (2002) 145-153
8. Bohlius J., Wilson J., Seidenfeld J., Piper M., Schwarzer G., Sandercock J., et al. Recombinant human erythropoietin and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98 (2006) 708-714
9. Wilson J., Yao G.L., Raftery J., Bohlius J., Brunskill S., Sandercock J., et al. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributed to cancer treatment. Health Technol Assess 11 (2007) 1-120
10. Littlewood T.J., Bajetta E., Nortier J.W., Vercammen E., and Rapoport B. Effects of epoietin alpha on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double blind, placebo-controlled trial. J Clin Oncol 19 (2001) 2865-2874
11. Bohlius J., Langensiepen S., Schwartzer G., Seidenfeld J., Piper M., Bennett C., et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97 (2005) 489-498
12. Raine A.E.G. Hypertension, blood viscosity and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet i (1988) 97
13. Henke N., Laszig R., Rube C., Schafer U., Haase K.D., Schilcher B., et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
14. Leyland-Jones B., Semiglazov V., Pawlicki M., Pienkowski T., Tjulandin S., Manikhas G., et al. Maintaining normal hemoglobin levels with epoietin alpha in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23 (2005) 5960-5972
15. Nowrousian M., Dunst J., and Vaupel P. Erythropoietin-stimulating agents: favorable safety profile when used as indicated. Strahlenther Onkol 184 (2008) 121-136
16. Bokemeyer C., Aapro M.S., Courdi A., Foubert J., Link H., Osterborg A., et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40 (2004) 2201-2216
17. Jones M., Schenkel B., Just J., and Fallowfield L. Epoietin alpha improves quality of life in patients with cancer: results of meta-analysis. Cancer 101 (2004) 1720-1732
18. Cortes J., O'Brien S., Quintas A., Giles F., Shan J., Rios M.B., et al. Erythropoietin is effective in improving the anemia induced by imatinub mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer 100 (2004) 2396-2402
19. Caro J.J., Salas M., Ward A., and Goss G. Anemia is an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91 (2001) 2214-2221
20. Wright J.R., Ung Y.C., Julian J.A., Pritchard K.I., Whelan T.J., Smith C., et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25 (2007) 1027-1032
21. Henke M., Mattern D., Pepe M., Bézay C., Weissenberger C., and Werner M. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J Clin Oncol 24 (2006) 4708-4713
22. Khuri F.R. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 356 (2007) 2245-2248
23. Acs G., Acs P., Beckwith S.M., Pitts R.L., Clement E., Wong K., et al. Erythropoietin and erythropoietin receptor expression in human lung cancer. Cancer Res 61 (2001) 3561-3565
24. Yasuda Y., Fujita Y., Matsuo T., Koinuma S., Hara S., and Tazaki A. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24 (2003) 1021-1029
25. Dunlop E.A., Maxwell A.P., and Lappin T.R. Impaired downregulation following erythropoietin receptor activation in non-small cell lung carcinoma. Stem Cells 25 (2007) 380-384
26. Gewirtz D.A., Di X., Walker T.D., and Sawyer S.T. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs. Clin Cancer Res 12 (2006) 2232-2238
27. Lamontagne K.R., Butler J., Marshall D.J., Tullai J., Gechtman Z., Hall C., et al. Recombinant epoietins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther 5 (2006) 347-355
28. Liu W.T., Powels T., Shamash J., Propper D., Oliver T., and Joel S. Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensititivity. Oncogene 23 (2004) 981-990
29. Acs G., Zhang P.J., Mc Grath C.M., Acs P., Mc Broom J., Mohyeldin A., et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 162 (2003) 1789-1806
30. Kumar S.M., Acs G., Fang D., Herlyn M., Elder D.E., and Xu X. Functional erythropoietin autocrine loop in melanoma. Am J Pathol 166 (2005) 823-830
31. Lai S.Y., Childs E.E., Xi S., Coppelli F.M., Gooding W.E., Wells A., et al. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 24 (2005) 4442-4449
32. Arcasoy M.O., Amin K., Karayal A.F., Chou S.C., Raleigh J.A., Varia M.A., et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 82 (2002) 911-918
33. Kayser K., and Gabius H.J. Analysis of expression or erythropoietin-binding sites in human lung carcinoma by the biotinylates ligand. Zentralbl Pathol 138 (1992) 266-270
34. Westenfelder C., and Baranowski R.L. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58 (2000) 647-657
35. Ribatti D., Marzullo A., Nico B., Crivellato E., Ria R., and Vacca A. Erythropoietin as an angiogenic factor in gastric carcinoma. Histopathology 42 (2003) 246-250
36. Ribatti D., Marzullo A., Gentile A., Longo V., Nico B., Vacca A., et al. Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma. Histopathology 50 (2007) 591-596
37. Yasuda Y., Musha T., Tanaka H., Fujita Y., Fujita H., and Utsumi H. Inhibition of erythropoietin sinaling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer 84 (2001) 836-843
38. Ribatti D., Poliani P.L., Longo V., Mangieri D., Nico B., and Vacca A. Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma. Histopathology. 50 (2007) 636-641
39. Batra S., Perelman N., Luck L.R., Shimada H., and Malik P. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 83 (2003) 1477-1487
40. Yasuda Y., Fujita Y., Masuda S., Musha T., Ueda K., Tanaka H., et al. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 23 (2002) 1797-1805
41. Kokhaei P., Abdalla A.O., Hansson L., Mikaelsson E., Kubbies M., Haselbecj A., et al. Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies. Clin Cancer Res 13 (2007) 3536-3554
42. Eliott S., Busse L., Bass M.B., Lu H., Sarosi I., Sinclair A.M., et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 107 (2006) 1892-1895
43. Brown V.W., Maxwell P., Graham A.N., Yakkundi A., Dunlop E.A., Shi Z., et al. Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem Cells 25 (2007) 718-722
44. Della Ragione F., Cucciolla V., Borriello A., Oliva A., and Perrotta S. Erythropoietin receptors on cancer cells: a still open question. J Clin Oncol 25 (2007) 1812-1813
45. Kirkeby A., van Beek J., Nielsen J., Leist M., and Helboe L. Functional and immunochemical characterization of different antibodies against erythropoietin receptor. J Neurosci Methods 164 (2007) 50-58
46. Laugsch M., Metzen E., Svensson T., Depping R., and Jelkmann W. Lack of functional erythropoietin receptors on cancer cell lines. Int J Cancer 122 (2008) 1005-1011
47. Ragione F.D., Cucciolla V., Borriello A., and Oiva A. Erythropoietin receptors on cancer cells: still an open question. J Clin Oncol 25 (2007) 1812-1813
48. Sturiale A., Campo S., Crasci E., Coppolino G., Bolignano D., Grasso G., et al. Erythropoietin and its lost receptor. Nephrol Dial Transplant 22 (2007) 1484-1485
49. Sinclair A.M., Rogers N., Busse L., Archibeque I., Brown W., Kassner P.D., et al. Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. Br J Cancer 98 (2008) 1059-1067
50. Pajonk F., Weil A., Sommer A., Suwinski R., and Henke M. The erythropoietin-receptor pathway modulates survival of cancer cells. Oncogene 23 (2004) 8987-8991
51. Ribatti D., Vacca A., Roccaro A.M., Crivellato E., and Presta M. Erythropoietin as an angiogenic factor. Eur J Clin Invest 33 (2003) 891-896
52. Anagnostou A., Liu Z., Steiner M., Chin K., Lee E.S., Kessimian N., et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 91 (1994) 3974-3978
53. Anagnostou A., Lee E.S., Kessimian N., Levison R., and Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 87 (1990) 5982-5987
54. Yamaji R., Okada T., Moriya M., Naito M., Tsuruo T., Miyatake K., et al. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem 239 (1996) 494-500
55. Ribatti D., Presta M., Vacca A., Ria R., Giuliani R., Dell'Era P., et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93 (1999) 2627-2636
56. Ashley R.A., Dubuque S.H., Dvorak B., Woodward S.S., Williams S.K., and Kling P.J. Erythropoietin stimulates vasculogenesis in neonatal rat mesenteric microvascular endothelial cells. Pediatr Res 51 (2002) 472-478
57. Carlini R.G., Reyes A.A., and Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 55 (1995) 546-553
58. Carlini R.G., Dusso A.S., Obialo C.I., Alvarez U.M., and Rothstein M. Recombinant human erythropoietin (rHuEpo) increases endothelin-1 release by endothelial cells. Kidney Int 43 (1993) 1010-1015
59. Vogel V., Kramer H.J., Backer A., Meyer-Lehnert H., Jelkmann W., and Fandrey J. Effects of erythropoietin on endothelin-1 synthesis and cellular calcium messanger system in vascular endothelial cells. Am J Hypertens 10 (1997) 289-297
60. Olujohungbe A., Handa S., and Holmes J. Do erythropoietin accelerate malignant transformation in multiple myeloma?. Postgrad Med J 73 (1987) 163-164
61. Bunworasate U., Arnouk H., Mindermal H., O'Loughlin K.L., Sait S.N.J., Barcos M., et al. Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia. Blood 98 (2001) 3492-3494
62. Ribatti D. A potential role of erythropoietin in angiogenesis associated with myelodysplastic syndromes. Leukemia 16 (2002) 1890
63. Khuri F.R. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 356 (2007) 2445-2448
64. Rizzo J.D., Somerfield M.R., Hagerty K.L., Seidenfeld J., Bohlius J., Bennett C.L., et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/Americal Society of Hematology clinical practice guideline update. J Clin Oncol 26 (2008) 132-149
65. Leading Edge. Erythropoietin analogues: an unnecessary class of drugs. Lancet Oncol 2008;9:81.